<http://schema.org/description>
"The FDA&amp;#39;s rejection of Lilly&amp;#39;s SGLT-2 inhibitor over manufacturing issues at a partner is another self-inflicted operational challenge. "^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fool.com/investing/general/2014/03/06/what-does-this-rejection-mean-for-eli-lilly.aspx>